Posts tagged non-small cell lung cancer
Chi-Med initiates fruquintinib clinical trial in U.S.

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.

Read More
Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21.

Read More
Ladenburg starts Leap Therapeutics at buy

Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.

Read More
HCW starts OSE Immunotherapeutics at buy

H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.

Read More
Roth resumes coverage of Viralytics at buy

Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30.

Read More
HCW starts OncoMed Pharma at buy

H.C. Wainwright has launched coverage of OncoMed Pharmaceuticals (NASDAQ:OMED) with a “buy” rating and $20 price target. The stock closed at $11.87 on Wednesday.

“We believe OncoMed is entering a year of dramatic changes with upcoming opt-in decisions for its lead drug candidates expected from its three partners: Celgene, Bayer and GlaxoSmithKline,” writes analyst Shaunak Deepak.

Read More
ARIAD reports updated data in pivotal ALTA study

ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease progression on crizotinib therapy.

The data show that, of patients on the 180 mg regimen (Arm B) with a median follow-up of 8.3 months, 54% achieved a confirmed objective response, the trial’s primary endpoint. In this arm, the median progression free survival exceeded one year (12.9 months) in this post-crizotinib setting.

Read More